The contract research organization (CRO) landscape is entering a new phase, marked by accelerated growth and a redefinition of its role in drug development. No longer seen as simple execution partners, CROs are becoming integral contributors to strategic decision making. As a result, functional service provider (FSP) models have become the dominant procurement approach, with sponsors increasingly expecting both flexibility and domain expertise from their partners. [1,2,3]

This market evolution, driven by the rapid integration of AI, shifting regulatory expectations, and the growing complexity of clinical development are all accelerating demand for deeper expertise in biometrics, data science, and innovative trial design. At the same time, the continued rise of the APAC region is expanding the need for partners who understand the nuances of local regulatory landscapes and can navigate them with confidence.

For sponsors, recognising these drivers of CRO growth isn’t just about tracking market trends – it’s a way to anticipate where strategic partnerships can unlock new value. By understanding how the ecosystem is evolving, organisations can spot opportunities to strengthen collaboration models and identify capability gaps that may be holding their own development efforts back.

Growth in the APAC Region

The Asia-Pacific (APAC) region has driven clinical trial growth for the past five years, with 2025 revenues reaching $17.5 billion which is equivalent to 19% of global market revenue. [4,5] This trend shows no sign of stopping with the APAC clinical trials market expected to double in size by 2033. [5,6] 

This growth is fuelled by a powerful combination of factors: a large and diverse patient population, sustained government investment, and a regulatory environment that is evolving to support innovation. At the same time, the region’s accelerated adoption of digital and data‑collection technologies is enabling more efficient, data‑rich research than ever before.

This momentum is reinforced by a surge in R&D activity and a clear shift toward outsourcing, as sponsors look to tap into APAC’s expanding capabilities. The availability of cost‑effective resources continues to draw a growing number of clinical trials to the region, creating a virtuous cycle of investment, expertise and opportunity. Together, these forces are positioning APAC not just as a fast‑growing market, but as a strategic hub shaping the future of global drug development. [7] 

However, these factors present challenges for sponsors as well as opportunities. With more data points being collected than ever before, older manual methods of data review have become impractical. Sponsors are increasingly looking reshape existing operations through the deployment of AI-enabled data management, including the use of machine learning (ML)-driven analytics, and they expect their workforce to have knowledge of these tools. [8] Variations in guidance and a rapidly changing regulatory environment can also add complexity to clinical trial planning and execution. While regulatory reforms intended to streamline drug development and approval are likely to generate sponsor benefits in the long term, in the short term they increase the requirement for in-depth local knowledge.

Both challenges demonstrate why CROs have become so invaluable to sponsors. Firstly, specialist CROs can provide user-friendly tools which allow research teams to leverage data value effectively. Techniques like AI-driven data visualization, for example, can create a ripple effect of expertise throughout an organization as they allow non-specialist staff to unlock insights more easily. Secondly, nimble CROs with regional expertise can provide much needed insight into local requirements with the flexibility needed to ensure regulatory compliance.

Increasing Trial Complexity

The rare disease market is expected to grow at a CAGR of 11.6% from 2025 to 2030 and more than half of novel drugs approved by the FDA in 2025 were rare disease treatments. [9,10] This growth is driving demand for adaptive trial designs, real-world data (RWD) integration and validated digital endpoints as traditional trial designs struggle to cope with the complexities and challenges of precision medicine and rare disease research. [1] 

To advance the next generation of clinical science, sponsors need access to deep expertise in innovative trial design. That requires close partnership with statisticians and data scientists who can translate emerging methodologies into practical, high‑impact study strategies. Approaches such as external control arms, data augmentation and synthetic patient cohorts are already demonstrating their value – reducing sample sizes, shortening timelines and still delivering the rigorous evidence needed to forecast long‑term outcomes and inform regulatory decisions. These capabilities are quickly becoming essential tools for sponsors looking to accelerate development without compromising scientific integrity. [11] 

Shifting Regulatory Expectations on Data and AI

In its Global Action Plan for Clinical Trial Ecosystem Strengthening the World Health Organization (WHO) calls for accelerated adoption of AI to improve the efficiency and quality of study design, data collection, management and analysis, and the dissemination of results. [12] The FDA has also published draft guidance designed to facilitate the use of Bayesian methodologies to help drug developers make better use of available data, conduct more efficient clinical trials, and deliver safe and effective treatments to patients sooner. [13]

While small biotechs are more likely to lack the in-house expertise needed to implement data-driven trial ecosystems, even large pharmaceutical companies can struggle to adapt to shifting AI and data expectations. Again, this is an area where specialist CROs can offer real value – delivering centralized solutions to collect, clean and audit data, enabling informed decision making and accelerating approval.

Conclusion

Drug development is increasingly precise, global and technology enabled. In this environment, sponsors should carefully consider how strategic outsourcing can help them harness the expertise which is most beneficial to them. 

The factors driving CRO growth are the same as those shifting the focus of global drug development. Understanding these factors can help sponsors choose strategic partners who can provide the right operational, functional and technical support, as well as therapeutic expertise.

Ultimately, effective CRO partnerships are an invaluable component of any strategy for success in an era of clinical trial transformation.

References

1. https://www.clinicalleader.com/doc/cro-industry-outlook-the-next-stage-of-clinical-trial-transformation-0001
2. https://nitesh_cp.rodpub.com/issues/2020-06-01/view_features/functional-service-provision-vs-full-service-outsourcing/
3. https://www.bcg.com/publications/2024/big-changes-to-pharma-cros
4. https://www.clinicaltrialsarena.com/sponsored/the-top-five-global-biotech-trends-of-the-last-five-years/
5. https://www.fortunebusinessinsights.com/industry-reports/contract-research-organization-cro-services-market-100864
6. https://www.grandviewresearch.com/industry-analysis/asia-pacific-clinical-trials-market-report
7. https://www2.deloitte.com/tw/en/pages/life-sciences-and-healthcare/articles/gx-future-lshc-asia-pacific.html
8. https://pmc.ncbi.nlm.nih.gov/articles/PMC10720846/
9. https://www.grandviewresearch.com/industry-analysis/rare-diseases-treatment-market-report
10. https://www.fiercepharma.com/pharma/2025-drug-approvals
11. https://phastar.com/knowledge-centre/publications/leveraging-real-world-data-for-in-silico-trials-enhancing-clinical-development-and-regulatory-confidence/
12. https://iris.who.int/server/api/core/bitstreams/dfaa5d87-dd9e-4236-a427-65a122d94409/content
13. https://www.fda.gov/news-events/press-announcements/fda-issues-guidance-modernizing-statistical-methods-clinical-trials

Dr. Stephen Corson is an Associate Director of Statistics and Technical Solutions who has been with Phastar since 2018. During his time at Phastar, Stephen has provided statistical support to trials in all phases in multiple therapeutic areas (oncology, hepatology, respiratory, ophthalmology). He currently supports RWE studies in Oncology and engages with industry teams to deliver in house training and identify the best solutions to the challenges they face. Stephen joined Phastar from Academia where he was a lecturer and director of the Mathematics and Statistics Consultancy and Training unit.